AR034153A1 - Compuesto quinolinahidrazona, el uso de un compuesto quinolinahidrazona para la manufactura de un agente antioxidante y de un agente para marcar o inhibir quimicamente la agregacion de fibrillas amiloides y permitir su asociacion, metodo para tenir fibrillas amiloides, un metodo para detectar dichos - Google Patents
Compuesto quinolinahidrazona, el uso de un compuesto quinolinahidrazona para la manufactura de un agente antioxidante y de un agente para marcar o inhibir quimicamente la agregacion de fibrillas amiloides y permitir su asociacion, metodo para tenir fibrillas amiloides, un metodo para detectar dichosInfo
- Publication number
- AR034153A1 AR034153A1 ARP010104465A ARP010104465A AR034153A1 AR 034153 A1 AR034153 A1 AR 034153A1 AR P010104465 A ARP010104465 A AR P010104465A AR P010104465 A ARP010104465 A AR P010104465A AR 034153 A1 AR034153 A1 AR 034153A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- agent
- quinolinahidrazona
- aryl
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000004220 aggregation Methods 0.000 title abstract 3
- 230000002776 aggregation Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 102000001049 Amyloid Human genes 0.000 abstract 3
- 108010094108 Amyloid Proteins 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- WZEOZJQLTRFNCU-UHFFFAOYSA-N trifluoro(trifluoromethoxy)methane Chemical compound FC(F)(F)OC(F)(F)F WZEOZJQLTRFNCU-UHFFFAOYSA-N 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 102000029797 Prion Human genes 0.000 abstract 1
- 108091000054 Prion Proteins 0.000 abstract 1
- -1 benzopyridinyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Un compuesto quinolinahidrazona, que comprende la fórmula (1) o una sal, éster, solvato o prodroga farmacéuticamente aceptable de la misma, en la cual: R1, R2, R3, R4 y R5 se seleccionan de manera independiente del grupo compuesto por hidrógeno, alquilo, cicloalquilo, arilo, trifluorometilo, trifluorometiléter, halo, y un grupo de la fórmula -OR7, donde R7 es alquilo o arilo; y R6 es un grupo benzopiridinilo sustituido de manera opcional con uno a tres sustituyentes seleccionados del grupo compuesto por hidrógeno, alquilo, cicloalquilo, arilo, trifluorometilo, trifluormetiléter, halo, y un grupo de la fórmula -OR7; donde tales grupos alquilo en cada ocurrencia son sustituidos de manera opcional con alcoxi, arilo, o halo; tales grupos arilo en cada ocurrencia son sustituidos de manera opcional con alquilo, alcoxi o halo; y uno o más átomos en el compuesto de la fórmula (1) es reemplazado de manera opcional con un átomo radiomarcado; el uso de un compuesto de quinolinahidrazona para la manufactura de un agente antioxidante y un agente para marcar o inhibir químicamente la agregación de fibrillas amiloides y permitir su asociación, método para tenir fibrillas amiloides, un método para detectar dichos depósitos, y una proteína prion, y un complejo que comprende dichos compuestos para diagnosticar y tratar las condiciones relacionadas con el amiloide y los compuestos útiles para las mismas, permitiendo detectar, visualizar por imágenes, monitorear, diagnosticar y tratar condiciones caracterizadas por la unión o la agregación de fibrillas amiloides.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23461100P | 2000-09-22 | 2000-09-22 | |
| US09/667,357 US6589504B1 (en) | 2000-09-22 | 2000-09-22 | Compounds and methods for diagnosing and treating amyloid-related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034153A1 true AR034153A1 (es) | 2004-02-04 |
Family
ID=22882072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104465A AR034153A1 (es) | 2000-09-22 | 2001-09-21 | Compuesto quinolinahidrazona, el uso de un compuesto quinolinahidrazona para la manufactura de un agente antioxidante y de un agente para marcar o inhibir quimicamente la agregacion de fibrillas amiloides y permitir su asociacion, metodo para tenir fibrillas amiloides, un metodo para detectar dichos |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6589504B1 (es) |
| EP (1) | EP1318982A1 (es) |
| AR (1) | AR034153A1 (es) |
| AU (1) | AU2001289123A1 (es) |
| PE (1) | PE20020452A1 (es) |
| WO (1) | WO2002024652A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311893B2 (en) | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
| US20020115717A1 (en) * | 2000-07-25 | 2002-08-22 | Francine Gervais | Amyloid targeting imaging agents and uses thereof |
| CA2441206A1 (en) | 2001-03-19 | 2002-09-26 | Gyros Ab | Characterization of reaction variables |
| DE10230838B4 (de) * | 2002-07-04 | 2005-02-03 | Mediquant Gmbh | Diagnostische Verwendung von pharmazeutischen Substanzen |
| US20080063599A1 (en) * | 2002-11-18 | 2008-03-13 | Jorge Setoain Quinquer | Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils |
| US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| AU2005289808B2 (en) * | 2004-09-24 | 2011-11-03 | The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense | Method of treating organophosphorous poisoning |
| US20060252819A1 (en) * | 2005-04-07 | 2006-11-09 | Astrum Therapeutics Pty Ltd | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus |
| WO2007056580A2 (en) * | 2005-11-08 | 2007-05-18 | Pharmadyn, Inc. | Methods and compositions for treating diseases associated with pathogenic proteins |
| US7737183B2 (en) * | 2006-10-17 | 2010-06-15 | The Regents Of The University Of California | β-amyloid and neurofibrillary tangle imaging agents |
| US9750705B2 (en) | 2012-08-31 | 2017-09-05 | The Regents Of The University Of California | Agents useful for treating obesity, diabetes and related disorders |
| EP3478288A4 (en) * | 2016-07-01 | 2020-03-04 | Prana Biotechnology Ltd | METHOD FOR TREATING IMMUNGLOBULIN LIGHT CHAIN AMYLOIDOSIS |
| WO2023080687A1 (ko) * | 2021-11-03 | 2023-05-11 | 가천대학교 산학협력단 | 아밀로이드 베타 멀티머 저해 약물의 고속 대량 스크리닝 방법 및 독소루비신 또는 이의 유도체를 포함하는 아밀로이드 베타의 올리고머화 또는 섬유화 억제용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3646019A (en) | 1968-10-26 | 1972-02-29 | Smith Kline French Lab | Anticestode hydrazinoquinolines |
| JPS5867616A (ja) | 1981-10-15 | 1983-04-22 | Tanabe Seiyaku Co Ltd | 腸溶性マイクロカプセル |
| IT1192015B (it) | 1986-06-27 | 1988-03-31 | Tecnocar Spa | Filtro per lubrificanti di motori a combustione interna con riserva di additivi |
| US5164404A (en) | 1991-03-15 | 1992-11-17 | Neurosearch A/S | Hydrazone derivatives and their use |
| AU7043894A (en) | 1993-05-28 | 1994-12-20 | Miriam Hospital, The | Composition and method for (in vivo) imaging of amyloid deposits |
| FR2715155B1 (fr) | 1994-01-19 | 1996-07-26 | Mayoly Spindler | Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation. |
| US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| US6417178B1 (en) | 1994-07-19 | 2002-07-09 | University Of Pittsburgh | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
| GB9416007D0 (en) | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
| HUP9900426A3 (en) | 1995-05-01 | 2001-12-28 | Univ Pittsburgh Pittsburgh | Amyloid binding azoderivatives, preparation thereof and use of these compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| WO1997016194A1 (en) | 1995-11-02 | 1997-05-09 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
| US5972956A (en) | 1995-11-02 | 1999-10-26 | Warner-Lambert Company | Inhibition of amyloidosis by 9-acridinones |
| WO1997026919A2 (en) | 1996-01-24 | 1997-07-31 | Warner-Lambert Company | Method of imaging amyloid deposits |
| US5891909A (en) | 1996-03-29 | 1999-04-06 | 3-Dimensional Pharmaceuticals, Inc. | Amidinohydrazones as protease inhibitors |
| US6054114A (en) | 1996-05-08 | 2000-04-25 | Massachusetts Institute Of Technology | Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro |
| GB9613433D0 (en) | 1996-06-26 | 1996-08-28 | Pharmacia Spa | Fluoro labelled anthracyclinone and anthracycline derivatives |
| DE19649971A1 (de) | 1996-11-19 | 1998-05-28 | Diagnostikforschung Inst | Optische Diagnostika zur Diagnostik neurodegenerativer Krankheiten mittels Nahinfrarot-Strahlung (NIR-Strahlung) |
| JP3980833B2 (ja) | 1998-08-20 | 2007-09-26 | リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | βアミロイド斑及び神経原線維変化の標識方法 |
-
2000
- 2000-09-22 US US09/667,357 patent/US6589504B1/en not_active Expired - Fee Related
-
2001
- 2001-09-17 AU AU2001289123A patent/AU2001289123A1/en not_active Abandoned
- 2001-09-17 WO PCT/US2001/029010 patent/WO2002024652A1/en not_active Application Discontinuation
- 2001-09-17 EP EP01968919A patent/EP1318982A1/en not_active Withdrawn
- 2001-09-21 PE PE2001000951A patent/PE20020452A1/es not_active Application Discontinuation
- 2001-09-21 AR ARP010104465A patent/AR034153A1/es unknown
-
2003
- 2003-04-23 US US10/421,126 patent/US20030219377A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002024652B1 (en) | 2002-06-27 |
| PE20020452A1 (es) | 2002-05-17 |
| WO2002024652A1 (en) | 2002-03-28 |
| EP1318982A1 (en) | 2003-06-18 |
| AU2001289123A1 (en) | 2002-04-02 |
| US6589504B1 (en) | 2003-07-08 |
| US20030219377A1 (en) | 2003-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034153A1 (es) | Compuesto quinolinahidrazona, el uso de un compuesto quinolinahidrazona para la manufactura de un agente antioxidante y de un agente para marcar o inhibir quimicamente la agregacion de fibrillas amiloides y permitir su asociacion, metodo para tenir fibrillas amiloides, un metodo para detectar dichos | |
| AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
| ES2528797T3 (es) | Compuestos de aza-benzotiofenilo y métodos de uso | |
| EA200701035A1 (ru) | Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR010376A1 (es) | Compuestos con efecto analgesico, su uso para la fabricacion de medicamentos, agentes de diagnostico, composicion farmaceutica, procedimiento para la preparacion de dichos compuestos y compuestos intermediarios | |
| CO5650247A2 (es) | Compuestos de indazol 3,5 disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular | |
| ES2647664T3 (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD) | |
| BR112018012106A2 (pt) | forma cristalina de inibidor de btk quinase e método de preparação da mesma | |
| AR055212A1 (es) | Compuestos heterociclicos como bloqueantes del canal ionico p2x7 | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| RS52245B (en) | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THErapeutic Use | |
| UY29346A1 (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
| AR051780A1 (es) | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| HUP0301607A2 (hu) | Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AR053149A1 (es) | Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis | |
| AR058701A1 (es) | Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| TW200740795A (en) | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | |
| ATE423765T1 (de) | Ep2-rezeptoragonisten | |
| AR040203A1 (es) | Combinacion de un inhibidor del reflujo y una imidazopiridina para el tratamiento de la gerd | |
| CL2020000096A1 (es) | Uso de wx-uk1 y su profármaco, wx-671, para el tratamiento de enfermedades no cancerosas. | |
| AR057558A1 (es) | Compuestos de cinolincarboxamida y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |